Polycythemia vera and agnogenic myeloid metaplasia.
Age complications bring these patients to primary physicians more frequently than would be expected from incidence or prevalence statistics alone. Therapy is symptomatic. Termination in acute leukemia occurs in both conditions and the risk may be increased by radiation or myelosuppressive drugs. Careful management can prolong survival in polycythemia vera and improve the quality of life in both conditions.
D000477:Alkylating Agents / Q000627:therapeutic use; D000728:Androgens / Q000627:therapeutic use; D001815:Bloodletting; D004911:Erythrocyte Volume; D005260:Female; D006400:Hematocrit; D006410:Hematopoiesis; D006801:Humans; D011087:Polycythemia Vera / Q000175:diagnosis* / Q000628:therapy; D055728:Primary Myelofibrosis / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy; D011379:Prognosis; D013156:Splenectomy; D013163:Splenomegaly / Q000175:diagnosis
D000477:Alkylating Agents; D000728:Androgens